Oxidative Damage May Lead to Neurocognitive Decline
the Cancer Therapy Advisor take:
Oxidative damage may contribute to chemotherapy-associated neurocognitive decline in survivors of childhood acute lymphoblastic leukemia (ALL), according to a recent study published online ahead of print in the Journal of Clinical Oncology.
Researchers led by Peter Cole, MD, of the Albert Einstein College of Medicine examined genomic DNA that was isolated from bone marrow in 350 pediatric leukemia survivors.
“This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline,” they stated.
These polymorphisms were selected based on prior literature. Multivariable logistic regression models were used to estimate the association between genotype and neurocognitive outcomes.
They found that inferior cognitive or behavioral outcomes were associated with polymorphisms in three genes (NOS3, SLCO2A1, and COMT) that were related to oxidative stress or neuroinflammation.
Oxidative damage may contribute to chemotherapy-associated neurocognitive decline in survivors of childhood ALL.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer